Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Adaptimmune Therapeutics plc (NASDAQ: ADAP).

Full DD Report for ADAP

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADAP)

Adaptimmune Therapeutics PLC (ADAP) CEO James Noble on Q3 2018 Results - Earnings Call Transcript
Adaptimmune Therapeutics PLC (ADAP) Q3 2018 Earnings Conference Call November 6, 2018 08:00 AM ET Executives Juli Miller - Director of IR James Noble - CEO & Director Rafael Amado - Chief Medical Officer Adrian Rawcliffe - Chief Financial Officer Analysts Jonathan Cha...
Source: SeekingAlpha
Date: November, 06 2018 14:37
Adaptimmune beats by $0.05, beats on revenue
Adaptimmune (NASDAQ: ADAP ): Q3 GAAP EPS of $0.01 beats by $0.05 . More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 06 2018 07:34
Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update
Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells Continued dosing in Cohort 1 of AFP study, with anticipated dose escalation to Cohort 2 early 2019  ~$26 mill...
Source: GlobeNewswire
Date: November, 06 2018 07:30
Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018
PHILADELPHIA and OXFORD, United Kingdom, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S. markets open on...
Source: GlobeNewswire
Date: October, 25 2018 16:30
Shipping and Biotech top list of midday movers (10/22/2018)
Gainers:  ESEA +173% . JTPY +142% . TOPS +108% . NETE +64% . GLBS +54% . ARII +51% . DCIX +50% . PXS +40% . SINO +35% . NVMM +32% . More news on: Euroseas Ltd., JetPay Corporation, TOP Ships Inc., Stocks on the move, , Top stock market news, Read mo...
Source: SeekingAlpha
Date: October, 22 2018 12:49
Premarket losers include HAS and PHG on Q3 earnings; healthcare companies down on presenting data at ESMO
ADAP   -34%  on disappointing SPEAR cell data. More news on: Adaptimmune Therapeutics plc, Aduro Biotech, Mirati Therapeutics, Inc., Stocks on the move, Top stock market news, , Read more ...
Source: SeekingAlpha
Date: October, 22 2018 09:20
Adaptimmune down 37% premarket on disappointing SPEAR cell data
Adaptimmune Therapeutics plc (NASDAQ: ADAP ) slumps  37%  premarket on light volume on the heels of its announcement of initial data from the first two cohorts of its ongoing studies evaluating its MAGE-A10 and MAGE-A4 SPEAR T-cells. The results were presented at ESMO in Munich. ...
Source: SeekingAlpha
Date: October, 22 2018 09:03
Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MA...
Source: GlobeNewswire
Date: October, 20 2018 10:45
Biotech Stocks Bloodied But Can Now Drive M&A
The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y...
Source: SeekingAlpha
Date: October, 19 2018 12:04
Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative
Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1...
Source: SeekingAlpha
Date: October, 18 2018 08:49

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0811.0010.5811.0010.43313,238
2018-05-1712.1112.0212.45911.90396,715
2017-02-034.574.544.574.366671,103
2017-02-024.454.484.564.4336,591
2017-02-014.314.504.584.31110,786

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-18101,272321,57131.4929Cover
2018-12-17121,776500,11424.3496Cover
2018-12-148,36749,38416.9427Cover
2018-12-1329,973110,38827.1524Cover
2018-12-12139,516989,13314.1049Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADAP.


About Adaptimmune Therapeutics plc (NASDAQ: ADAP)

Logo for Adaptimmune Therapeutics plc (NASDAQ: ADAP)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ADAP)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 30 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 12 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: March, 29 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 15 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 15 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: ADAP)

      Daily Technical Chart for (NASDAQ: ADAP)


      Stay tuned for daily updates and more on (NASDAQ: ADAP)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ADAP)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADAP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ADAP and does not buy, sell, or trade any shares of ADAP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/